PCSK9 — long a validated target for cholesterol lowering via monoclonal antibodies and siRNA — is reemerging as a focal point for gene‑editing strategies after Eli Lilly’s acquisition of Verve Therapeutics and its in vivo PCSK9 editing candidate. Analysis from Labiotech and industry sources maps how companies are migrating from antibodies and RNA to once‑and‑done editing approaches to secure durable LDL‑lowering. The takeover underscores industry appetite for durable cardiovascular interventions and consolidates capabilities in in vivo base‑editing and delivery. The move also raises manufacturing, safety and regulatory questions as companies advance gene‑editing assets into the clinic and seek scalable radiopharma or vector platforms that support one‑time therapies.